Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that Dr. Niranjan Sardesai, COO, will participate on a panel of senior vaccine experts at the 2012 BIO International Convention,the largest global event for the biotechnology industry. Dr. J. Joseph Kim, President and CEO, will present an overview of the company at the Marcum Microcap Conference, which is designed for investors interested in micro-cap companies.
2012 BIO International ConventionJune 18-21, 2012
Boston Convention & Exhibition Center, MA
PanelLeveraging New Development Paradigms to Address Infectious Diseases in the 21st CenturySession ID: 1201
Tuesday, June 19
10:00 AM - 11:30 a.m. ET
TopicThe "one bug, one vaccine" paradigm worked for years and eradicated some major diseases. Today's bugs are pathogens that either change rapidly or have many serotypes—and they command innovation throughout the vaccine value chain. The panel will discuss 21st century needs and the innovations necessary for new vaccines.
Participants
- Moderator: Stanley Plotkin
Consultant in Vaccinology, Sanofi Pasteur
- Jeffrey Almond
Vice President, Discovery Research and External R&D, Sanofi Pasteur
- Anthony Ford-Hutchinson
Independent Consultant, Ford-Hutchinson Consulting Ltd.
Retired Merck Senior Vice President, Vaccines Research and Development
- Christian W. Mandl
VP, Head of US Research, Novartis Vaccine & Diagnostics, Inc. and Global Head for all viral vaccine research projects
- Regina Rabinovich
Director, Enteric & Diarrheal Diseases and Pneumonia & Interim Director Malaria, Global Health Program, Bill & Melinda Gates Foundation
- Niranjan Sardesai
Chief Operating Officer, Inovio Pharmaceuticals
Marcum Microcap Investor ConferenceJune 20, 2012
45 East 45th Street, The Roosevelt Hotel
New York City, New York
Inovio PresentationWednesday, June 20
12:00 – 12:30 p.m. ET
J. Joseph Kim, PhD, President and CEO
The path to a better tuberculosis vaccine runs through Montana